What is the long-term trend for Tango Therapeutics's temporary equity par or stated value per share?

Over 5 years (2020 to 2025), Tango Therapeutics's temporary equity par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.

Tango Therapeutics TNGX Temporary Equity Par Or Stated Value Per Share

Temporary Equity Par Or Stated Value Per Share at other companies

Flagstar Bank FLG

$0.010.0%

BillionToOne, Inc. BLLN

0-100%

Kimberly-ClarkKMB

$1.250.0%

Las Vegas SandsLVS

$0.000.0%

International Flavors & FragrancesIFF

$0.130.0%

Raymond James FinancialRJF

$0.010.0%

Other financials

Income statement

See full

Revenue--100%

Operating income-$48.8M-14.7%

Net income-$45.5M-14.1%

EPS (diluted)-$0.32+11.1%

Balance sheet

See full

Cash & equivalents$160.0M+162%

Total debt$32.8M-11.3%

Total equity$391.5M+135%

Total assets$435.8M+58.9%

Cash flow

See full

Operating cash flow-$44.4M-6.4%

CapEx-$2.0K-104%

Free cash flow-$44.4M-6.3%

Valuation

See full

Market cap$4.55B+1,915%

Profitability

See full

Operating margin-206.2%-61.0pp

Net margin-188.2%-55.4pp

FCF margin-250.1%-49.4pp

Returns & leverage

See full

Return on equity-38.4%-10.5pp

Debt / equity0.1×-0.1×

Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:TemporaryEquityParOrStatedValuePerShare.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's temporary equity par or stated value per share.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tango Therapeutics's temporary equity par or stated value per share?: Tango Therapeutics (TNGX) reported temporary equity par or stated value per share of $0.00 in Q1 2026.
How has Tango Therapeutics's temporary equity par or stated value per share changed year-over-year?: Tango Therapeutics's temporary equity par or stated value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
What is the long-term trend for Tango Therapeutics's temporary equity par or stated value per share?: Over 5 years (2020 to 2025), Tango Therapeutics's temporary equity par or stated value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.